This is the first of a 5-part newsletter series. There is a second (28 Sep 2023) newsletter that expands on the EPA concept note, a third (12 Jan 2024) newsletter about ending the use of streptomycin spray on citrus crops, a 4th newsletter (27 Jan 2024) containing some additional resources, and a fifth newsletter (11
This is the third of a 5-part newsletter series. There is an initial 27 Sep 2023 newsletter introducing the EPA concept note, a second (28 Sep 2023) newsletter that expands on the EPA concept note, a 4th newsletter (27 Jan 2024) containing some additional resources, and a fifth newsletter (11 Oct 2024) about the EPA’s collaborative framework for evaluating the AMR risks of antibacterial and antifungal
Dear All, There are more details yet to come, but the EU Council (“the Council”) and the EU Parliament (EP) yesterday announced an agreement on the update to the EU General Pharmaceutical Legislation that includes transferable exclusivity vouchers (TEVs or TEEVs, depending on your preferred abbreviation). Here’s the key text from the EP’s press release:
Dear All (and with thanks to Frédéric Peyrane for leading on this newsletter): You will know that we eagerly watching the work in the EU on implementing a set of pull incentives based on use of ‘transferable data exclusivity voucher’ (TEV), also referred to as a ‘transferable exclusivity extension voucher’ (TEEV). In brief, the concept is that a TEEV
Dear All, Our colleagues in Europe have been busy! Along with yesterday’s announcement about transferrable exclusivity vouchers, we also had publication of the Horizon Europe Work Programme 2026-2027. It’s a really big program that includes within its Cluster 1 a trio of calls of interest to readers of this newsletter: HORIZON-HLTH-2027-01-DISEASE-08 call seeks projects developing
Dear All, I am pleased to learn that BARDA is holding a one-day innovation symposium on 20 Nov 2025. As you know, BARDA is a consistently creative funder of diverse medical countermeasures, including new antibiotics. For background, see these prior newsletters: 22 Jul 2025 newsletter: “BARDA RFP: Antibiotic for HABP/VABP or Bloodstream Infection” 5 Nov
Dear All, Today is a newsletter double-header! Coming hard on the heels of the opportunity to support an ESCMID petition to UNGA 2024, the UK today released the details of its next five-year action plan. Excitingly for this audience, there is an updated roadmap for the UK’s next steps in its subscription model. Here are
Dear All, I have learned that UK’s MHRA (Medicines & Healthcare products Regulatory Agency) is recruiting for the role of Chief Medical and Scientific Officer. As you would expect, the role is very senior! The person in the role will: Represent the MHRA across the medical and scientific communities Act as a senior advocate for evidence-based, effective
Dear All, BARDA has released a fascinating Sources Sought Notice (SSN) seeking data on antibacterials near, at, or beyond Phase 2. I’ve never seen one before, but an SSN is market research with which BARDA will “collect feedback from current and prospective antibiotic development partners” that will “serve as continued market research for potential future acquisitions
Dear All, Referring back to the actions planned following the 2024 UNGA HLM on AMR (UN General Assembly High-Level Meeting on AMR; 1 Oct 2024 newsletter and our dedicated UNGA 2024 webpage), you will hopefully recall the commitment to create an Independent Panel on Evidence for Action against AMR (IPEA). The broad idea is the